Knight Therapeutics Announces the Launch of the Tender Offer for remaining 48.8% of Grupo Biotoscana
MONTREAL, July 15, 2020 — Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. (“Knight“) today announced the launch of the tender offer and the release of the notice for the tender offer process filed by 1178991 CANADA INC. for the acquisition and delisting of all outstanding Brazilian Depositary Receipts of […]
Knight Announces Normal Course Issuer Bid
MONTREAL, July 10, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company “), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the “TSX”) of the Company’s Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB, the Company proposes to purchase, from […]
Knight Therapeutics Announces CVM Approval of the Tender Offer for remaining 48.8% of Grupo Biotoscana
MONTREAL, July 08, 2020 — Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. (“Knight” or “Offeror“) today announced that the Brazilian Securities and Exchange Commission (Comissão de Valores Mobiliários) (“CVM“) has approved the Tender Offer process filed by 1178991 CANADA INC. for the acquisition of all outstanding Brazilian Depositary Receipts […]
Knight Therapeutics Reports First Quarter 2020 Results
MONTREAL, June 26, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2020. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2020 […]
Knight Therapeutics Inc. announces voting results from the Annual Meeting
MONTREAL, June 25, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held in Montreal, Quebec (“Meeting”). Election of Directors Each director nominee listed in the Management Information Circular dated May 26, 2020 (“Circular”) was […]
Notice of Knight Therapeutics' First Quarter 2020 Results Conference Call
MONTREAL, June 18, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2020 financial results on Friday, June 26, 2020 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Therapeutics Inc. Announces Further Update on Extension of First Quarter 2020 Filings due to COVID-19
MONTREAL, May 29, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (ex USA) specialty pharmaceutical company, announced today, further to its news release dated April 30, 2020, that as a result of the COVID-19 impact, Knight will continue to rely on the temporary relief afforded by DÉCISION N°2020-PDG-0023 of the […]
Knight to Present at the Jefferies 2020 Virtual Global Healthcare Conference
MONTREAL, May 27, 2020 — Knight Therapeutics Inc. (TSX: GUD), a leading pan-American (ex- US) specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present at the Jefferies 2020 Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 9:00 AM ET. A copy of the presentation will be available at www.gud-knight.com. […]
Knight Therapeutics Inc. Announces Extension of First Quarter 2020 Filings due to COVID-19
MONTREAL, April 30, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (ex USA) specialty pharmaceutical company, announced today that as a result of the COVID-19 impact, Knight will be relying on the temporary relief afforded by DÉCISION N°2020-PDG-0023 of the Autorité des marchés financiers in respect of the obligation to […]
Knight Announces the Re-Launch of Trelstar® in Canada
MONTREAL, April 20, 2020 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has successfully taken over commercial activities from Debiopharm’s previous partner, Allergan. Knight licensed the exclusive rights to commercialize Trelstar® in Canada from Debiopharm, a Swiss-based, global biopharmaceutical company. “We are excited to re-launch […]
